Melanoma: A model for testing new agents in combination therapiesReport as inadecuate

Melanoma: A model for testing new agents in combination therapies - Download this document for free, or read online. Document in PDF available to download.

Journal of Translational Medicine

, 8:38

First Online: 20 April 2010Received: 04 March 2010Accepted: 20 April 2010DOI: 10.1186-1479-5876-8-38

Cite this article as: Ascierto, P.A., Streicher, H.Z. & Sznol, M. J Transl Med 2010 8: 38. doi:10.1186-1479-5876-8-38


Treatment for both early and advanced melanoma has changed little since the introduction of interferon and IL-2 in the early 1990s. Recent data from trials testing targeted agents or immune modulators suggest the promise of new strategies to treat patients with advanced melanoma. These include a new generation of B-RAF inhibitors with greater selectivity for the mutant protein, c-Kit inhibitors, anti-angiogenesis agents, the immune modulators anti-CTLA4, anti-PD-1, and anti-CD40, and adoptive cellular therapies. The high success rate of mutant B-RAF and c-Kit inhibitors relies on the selection of patients with corresponding mutations. However, although response rates with small molecule inhibitors are high, most are not durable. Moreover, for a large subset of patients, reliable predictive biomarkers especially for immunologic modulators have not yet been identified. Progress may also depend on identifying additional molecular targets, which in turn depends upon a better understanding of the mechanisms leading to response or resistance. More challenging but equally important will be understanding how to optimize the treatment of individual patients using these active agents sequentially or in combination with each other, with other experimental treatment, or with traditional anticancer modalities such as chemotherapy, radiation, or surgery. Compared to the standard approach of developing new single agents for licensing in advanced disease, the identification and validation of patient specific and multi-modality treatments will require increased involvement by several stakeholders in designing trials aimed at identifying, even in early stages of drug development, the most effective way to use molecularly guided approaches to treat tumors as they evolve over time.

Download fulltext PDF

Author: Paolo A Ascierto - Howard Z Streicher - Mario Sznol


Related documents